Adaptimmune Therapeutics PLC — Director's Dealing 2022

Feb 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2022-01-31

Reporting Person: Piccina Cintia (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-31	Option to purchase Ordinary Shares	$0.45	A	3376992	Acquired	2032-01-31	Ordinary Shares (3376992)	Direct
2022-01-31	Option to purchase Ordinary Shares	$0.0013	A	754200	Acquired		Ordinary Shares (754200)	Direct
2022-01-31	Option to purchase Ordinary Shares	$0.0013	A	335184	Acquired	2023-03-15	Ordinary Shares (335184)	Direct

Footnotes

F1: The exercise price was converted from GBP0.33 based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 844,248 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in monthly installments of 70,350 Ordinary Shares on the last day of each month from February 28, 2023 through December 31, 2025 and 70,494 Ordinary Shares on January 31, 2026.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 188,550 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in annual installments of 188,550 Ordinary Shares on the thirty-first of each January from January 31, 2024 through January 31, 2026.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

F6: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.